Skip to main content

Table 1 Patient demographics

From: An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a “no-treat zone”

Characteristics Patients with re-SABR (n = 14) Patients with CRT after SABR (n = 24)
Age (at time of recurrence), median (range) 74 (57–84) 70 (49–85)
Sex   
Male
Female
8 (57%)
6 (43%)
14 (58%)
10 (42%)
ECOG (at time of recurrence)   
0
1
2
3
0 (0%)
13 (93%)
1 (7%)
0 (0%)
4 (17%)
15 (63%)
5 (21%)
0 (0%)
Tumor stage (at initial presentation)   
T1
T2
12 (86%)
2 (14%)
22 (92%)
2 (8%)
Histology   
Adenocarcinoma
Squamous
Other
10 (71%)
4 (29%)
0 (0%)
16 (67%)
7 (29%)
1 (4%)
EBUS performed initially 10 (71%) 20 (83%)
Recurrence confirmed   
Biopsy
PET-CT
CT
7 (50%)
4 (29%)
3 (21%)
24 (100%)
0 (0%)
0 (0%)
Median time to recurrence from 1st SABR, mo (range) 20 (3–60) 16 (5–54)
Median follow-up time from the time of re-RT, mo (IQR) 36 (19–45) 18 (8–38)
OS after re-RT (95% CI)   
1-year rate, %
3-year rate, %
5-year rate, %
86% (54–96%)
63% (32–83%)
54% (24–76%)
70% (47–84%)
35% (17–54%)
16% (3–36%)